Literature DB >> 12103462

Brain single photon emission computed tomography findings in depressive pseudodementia patients.

Maeng Je Cho1, In Kyoon Lyoo, Dong Woo Lee, Jun Soo Kwon, Jae Sung Lee, Dong Soo Lee, June Key Jung, Myung Chul Lee.   

Abstract

BACKGROUND: Recently, there have been studies suggesting that depressive pseudodementia would include early-stage dementing disorder. Through the comparison of the 99mTc-HMPAO single photon emission computed tomography (SPECT) image of depressive pseudodementia subjects, healthy comparison subjects, depressed subjects free of cognitive impairment, and dementia of Alzheimer's type (DAT) subjects, we aimed to see part of pathophysiology of the depressive pseudodementia of elderly patients.
METHODS: Study subjects consisted of seven patients with depressive pseudodementia, seven healthy comparison subjects, seven patients with depression free of cognitive impairment, and eleven patients with DAT. Depression patients were diagnosed according to DSM-III-R. DAT patients were diagnosed by DSM III-R and NINCDS-ADRDA criteria of DAT. Other measures for assessment include Hamilton Rating Scale for Depression and Mini Mental State Exam. All underwent 99mTc-HMPAO SPECT scan. The images of each group were analyzed using statistical parametric mapping of Friston, which compares the images on voxel-by-voxel basis.
RESULTS: The results were as follows (1) The DAT group showed significant decreases of cerebral blood flow (CBF) in the right frontal, right temporal region, and both parietal regions as compared with control group (P < 0.05). (2) The depression group showed a significant decrease of CBF in the left frontal region as compared with control group (P < 0.05). (3) The depressive pseudodementia group showed significant decreases of CBF in both parietal regions as compared with control group (P < 0.05). (4) The depressive pseudodementia group showed significant decreases of CBF in the right temporal region and both parietal regions as compared with depression group (P < 0.05). (5) The DAT group showed significant decreases of CBF in the right temporal region, both frontal regions, and both parietal regions as compared with depressive pseudodementia group (P < 0.05). LIMITATIONS: The small number of subjects may make it difficult to generalize from our results. Because decreased CBF in depressive pseudodementia is found while the subjects were depressed, we cannot tell whether it is a state marker or a trait marker.
CONCLUSIONS: The depressive pseudodementia group showed decreased CBF in the temporo-parietal region, similar to that of the DAT group and different from that of the depression group.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12103462     DOI: 10.1016/s0165-0327(01)00301-9

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  11 in total

1.  Regional cerebral blood flow abnormalities in patients with primary hyperparathyroidism.

Authors:  Tevfik Fikret Cermik; Meryem Kaya; Betül Uğur-Altun; Deniz Bedel; Sakir Berkarda; Omer N Yiğitbaşi
Journal:  Neuroradiology       Date:  2007-01-05       Impact factor: 2.804

Review 2.  60 Years of Achievements by KSNM in Neuroimaging Research.

Authors:  Jae Seung Kim; Hye Joo Son; Minyoung Oh; Dong Yun Lee; Hae Won Kim; Jungsu Oh
Journal:  Nucl Med Mol Imaging       Date:  2022-01-15

3.  Cerebral perfusion (HMPAO-SPECT) in patients with depression with cognitive impairment versus those with mild cognitive impairment and dementia of Alzheimer's type: a semiquantitative and automated evaluation.

Authors:  W Staffen; J Bergmann; U Schönauer; H Zauner; M Kronbichler; S Golaszewski; G Ladurner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-10       Impact factor: 9.236

Review 4.  Dementia and its implications for public health.

Authors:  Daniel P Chapman; Sheree Marshall Williams; Tara W Strine; Robert F Anda; Margaret J Moore
Journal:  Prev Chronic Dis       Date:  2006-03-15       Impact factor: 2.830

5.  Changes in regional cerebral blood flow with Chaihu-Shugan-San in the treatment of major depression.

Authors:  Juan Qiu; Sui-Yu Hu; Guang-Qing Shi; Su-E Wang
Journal:  Pharmacogn Mag       Date:  2014-10       Impact factor: 1.085

6.  Quantification of Tc-99m-ethyl cysteinate dimer brain single photon emission computed tomography images using statistical probabilistic brain atlas in depressive end-stage renal disease patients: Correlation with disease severity and symptom factors.

Authors:  Heeyoung Kim; In Joo Kim; Seong-Jang Kim; Sang Heon Song; Kyoungjune Pak; Keunyoung Kim
Journal:  Neural Regen Res       Date:  2012-09-25       Impact factor: 5.135

Review 7.  Mood disorders in the elderly: prevalence, functional impact, and management challenges.

Authors:  Leandro da Costa Lane Valiengo; Florindo Stella; Orestes Vicente Forlenza
Journal:  Neuropsychiatr Dis Treat       Date:  2016-08-24       Impact factor: 2.570

8.  Combining SPECT and Quantitative EEG Analysis for the Automated Differential Diagnosis of Disorders with Amnestic Symptoms.

Authors:  Yvonne Höller; Arne C Bathke; Andreas Uhl; Nicolas Strobl; Adelheid Lang; Jürgen Bergmann; Raffaele Nardone; Fabio Rossini; Harald Zauner; Margarita Kirschner; Amirhossein Jahanbekam; Eugen Trinka; Wolfgang Staffen
Journal:  Front Aging Neurosci       Date:  2017-09-07       Impact factor: 5.750

9.  When Cognitive Decline and Depression Coexist in the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer's Disease from Late-Life Depression.

Authors:  Claudio Liguori; Mariangela Pierantozzi; Agostino Chiaravalloti; Giulia M Sancesario; Nicola B Mercuri; Flaminia Franchini; Orazio Schillaci; Giuseppe Sancesario
Journal:  Front Aging Neurosci       Date:  2018-02-23       Impact factor: 5.750

10.  (99m)Tc-hexamethyl propyleneamine oxime brain perfusion single photon emission computed tomography in characterization of dementia: an initial experience in Indian clinical practice.

Authors:  Amburanjan Santra; Gaurav Kumar Sinha; Rajarshi Neogi; Ramesh Kumar Thukral
Journal:  World J Nucl Med       Date:  2014-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.